| Literature DB >> 25208486 |
Alexandra Traister1, Mark Li1, Shabana Aafaqi1, Mingliang Lu1, Sara Arab2, Milica Radisic3, Gil Gross1, Fiorella Guido1, John Sherret1, Subodh Verma4, Cameron Slorach1, Luc Mertens1, Wei Hui1, Anna Roy5, Paul Delgado-Olguín6, Gregory Hannigan7, Jason T Maynes8, John G Coles1.
Abstract
Human dilated cardiomyopathy (DCM) manifests as a profound reduction in biventricular cardiac function that typically progresses to death or cardiac transplantation. There is no effective mechanism-based therapy currently available for DCM, in part because the transduction of mechanical load into dynamic changes in cardiac contractility (termed mechanotransduction) remains an incompletely understood process during both normal cardiac function and in disease states. Here we show that the mechanoreceptor protein integrin-linked kinase (ILK) mediates cardiomyocyte force transduction through regulation of the key calcium regulatory protein sarcoplasmic/endoplasmic reticulum Ca(2+)ATPase isoform 2a (SERCA-2a) and phosphorylation of phospholamban (PLN) in the human heart. A non-oncogenic ILK mutation with a synthetic point mutation in the pleckstrin homology-like domain (ILK(R211A)) is shown to enhance global cardiac function through SERCA-2a/PLN. Thus, ILK serves to link mechanoreception to the dynamic modulation of cardiac contractility through a previously undiscovered interaction with the functional SERCA-2a/PLN module that can be exploited to rescue impaired mechanotransduction in DCM.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25208486 DOI: 10.1038/ncomms5533
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919